CLEARSIDE BIOMEDICAL

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

21 Feb 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

07 Feb 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Leadership Team Update

06 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

02 Feb 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

22 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

10 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

09 Nov 2022 07:15:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

09 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

08 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

02 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

04 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

27 Sep 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

25 Aug 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

09 Aug 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

08 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

03 Aug 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

27 Jul 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

26 Jul 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

07 Jul 2022 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

14 Jun 2022 07:05:00 By Nasdaq GlobeNewswire